% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Her:157145,
author = {E. J. Her and A. Haworth and H. M. Reynolds and Y. Sun and
A. Kennedy and V. Panettieri and M. Bangert$^*$ and S.
Williams and M. A. Ebert},
title = {{V}oxel-level biological optimisation of prostate {IMRT}
using patient-specific tumour location and clonogen density
derived from mp{MRI}.},
journal = {Radiation oncology},
volume = {15},
number = {1},
issn = {1748-717X},
address = {London},
publisher = {BioMed Central},
reportid = {DKFZ-2020-01431},
pages = {172},
year = {2020},
abstract = {This study aimed to develop a framework for optimising
prostate intensity-modulated radiotherapy (IMRT) based on
patient-specific tumour biology, derived from
multiparametric MRI (mpMRI). The framework included a
probabilistic treatment planning technique in the effort to
yield dose distributions with an improved expected treatment
outcome compared with uniform-dose planning approaches.IMRT
plans were generated for five prostate cancer patients using
two inverse planning methods: uniform-dose to the planning
target volume and probabilistic biological optimisation for
clinical target volume tumour control probability (TCP)
maximisation. Patient-specific tumour location and clonogen
density information were derived from mpMRI and geometric
uncertainties were incorporated in the TCP calculation.
Potential reduction in dose to sensitive structures was
assessed by comparing dose metrics of uniform-dose plans
with biologically-optimised plans of an equivalent level of
expected tumour control.The planning study demonstrated
biological optimisation has the potential to reduce expected
normal tissue toxicity without sacrificing local control by
shaping the dose distribution to the spatial distribution of
tumour characteristics. On average, biologically-optimised
plans achieved $38.6\%$ (p-value: < 0.01) and $51.2\%$
(p-value: < 0.01) reduction in expected rectum and bladder
equivalent uniform dose, respectively, when compared with
uniform-dose planning.It was concluded that varying the dose
distribution within the prostate to take account for each
patient's clonogen distribution was feasible. Lower doses to
normal structures compared to uniform-dose plans was
possible whilst providing robust plans against geometric
uncertainties. Further validation in a larger cohort is
warranted along with considerations for adaptive therapy and
limiting urethral dose.},
cin = {E040},
ddc = {610},
cid = {I:(DE-He78)E040-20160331},
pnm = {315 - Imaging and radiooncology (POF3-315)},
pid = {G:(DE-HGF)POF3-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:32660504},
doi = {10.1186/s13014-020-01568-6},
url = {https://inrepo02.dkfz.de/record/157145},
}